Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 8093854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

  1991cited by this paper
• Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

  1991cited by this paper
• Relationships between the structure of taxol analogues and their antimitotic activity.

  1991cited by this paper
• A phase I study of Taxotere (RP 56976 NSC 628503) administered as a one hour intravenous infusion on a weekly basis

  1991cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• Taxol: a novel investigational antimicrotubule agent.

  1990influential reference
• Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma

  2023cites this paper
• Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography

  2022cites this paper
• Interactions between cardiology and oncology drugs in precision cardio-oncology.

  2021cites this paper
• Neurologic Complications

  2020cites this paper
• Cardiovascular Toxicities of Chemotherapy

  2020cites this paper
• Taxane‐Grafted Metal‐Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel‐Functionalized Titanate Nanotubes on Prostate Tumors

  2017cites this paper
• Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

  2017cites this paper
• Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients

  2016cites this paper
• Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

  2016cites this paper
• Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo

  2016cites this paper
• Development of RP-HPLC method for simultaneous determination of docetaxel and curcumin in rat plasma: Validation and stability

  2016cites this paper
• Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.

  2015cites this paper
• Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.

  2015cites this paper
• Poly(2-oxazoline)s as new drug delivery systems

  2015cites this paper
• Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics

  2014cites this paper
• An Automated Nanoparticle-Based Homogeneous Immunoassay for Determining Docetaxel Concentrations in Plasma

  2013cites this paper
• Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013cites this paper
• Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance

  2013cites this paper
• Emerging Drug Treatments for Solid Tumours

  2012cites this paper
• The Taxoids

  2012cites this paper
• Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.

  2012cites this paper
• Therapeutic options for treatment of Merkel cell carcinoma

  2011cites this paper
• Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences

  2011cites this paper
• Taxanes and Epothilones in Cancer Treatment

  2011cites this paper
• Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo

  2011cites this paper
• Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse

  2010cites this paper
• Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

  2010cites this paper
• PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression.

  2010cites this paper
• Single Tissue Samples from Head and Neck Squamous Cell Carcinomas are Representative Regarding the Entire Tumor’s Chemosensitivity to Cisplatin and Docetaxel

  2009cites this paper
• Management of peripheral neuropathy caused by microtubule inhibitors.

  2009cites this paper
• Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report

  2008cites this paper
• Docetaxel in the management of prostate cancer: current standard of care and future directions

  2008cites this paper
• Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: The role of genes associated with the NF‐κB pathway

  2008cites this paper
• Lessons learned from development of docetaxel.

  2008cites this paper
• Docetaxel in the management of prostate cancer: current standard of care and future directions.

  2008cites this paper
• Lessons learned from development of docetaxel

  2008cites this paper
• [Development of docetaxel in the adjuvant chemotherapy of breast cancer].

  2008cites this paper
• Alternative drug formulations of docetaxel: a review.

  2007cites this paper
• Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

  2007cites this paper
• Model-based drug development applied to oncology

  2007cites this paper
• A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.

  2006cites this paper
• Pharmacokinetic Optimization of Docetaxel Dosing

  2006cites this paper
• Les toxicités cardiovasculaires des traitements oncologiques

  2006cites this paper
• Tubulin interacting agents

  2006cites this paper
• Phase I Clinical Trial of Irinotecan ( CPT-11 ) , 7-Ethyl-1 O-[ 441-piperidino ) .1-piperidino ] carbonyloxy-camptothecin , and Cisplatin in Combination with Fixed Dose of Vindesine in Advanced Non-Small Cell Lung Cancer '

  2006cites this paper
• Drugs affecting growth of tumours

  2006cites this paper
• Preparation and characterization of taxane-containing liposomes.

  2005cites this paper
• Pharmacokinetics and pharmacodynamics of protein‐unbound docetaxel in cancer patients

  2005cites this paper
• The role of taxanes in the treatment of breast cancer

  2005cites this paper
• Cardiotoxicity of cancer therapy.

  2005cites this paper
• Docetaxel in the management of ovarian cancer

  2005cites this paper
• Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

  2005cites this paper
• Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublinesin vitro

  2004cites this paper
• Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.

  2004cites this paper
• Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

  2004cites this paper
• Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors

  2004cites this paper
• [Cardiovascular toxicity of some cancer agents (others than anthracyclines, fluoropyrimidines and trastuzumab)].

  2004cites this paper
• Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support

  2004cites this paper
• Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design

  2004cites this paper
• [Docetaxel and ovarian cancer].

  2004cites this paper
• Biotransformation of Paclitaxel (Taxol) by the Cell Suspension Cultures of Rauwolfia serpentina

  2004cites this paper
• Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer

  2004cites this paper
• Docetaxel and ketoconazole in advanced hormone‐refractory prostate carcinoma

  2003influential citation
• Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.

  2003cites this paper
• Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

  2003cites this paper
• Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.

  2003cites this paper
• Docetaxel as Neoadjuvant Chemotherapy in Patients With Advanced Cervical Carcinoma

  2003cites this paper
• Docetaxel (Taxotere®) in the treatment of prostate cancer

  2003cites this paper
• A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

  2003cites this paper
• Docetaxel: an alternative taxane in ovarian cancer

  2003cites this paper
• A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors

  2003cites this paper
• Atrial Fibrillation during Adjuvant Chemotherapy with Docetaxel: A Case Report

  2002cites this paper
• Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction.

  2001cites this paper
• Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.

  2001cites this paper
• Taxanes in lung cancer: a review with focus on the European experience.

  2001cites this paper
• New horizons in treating metastatic disease.

  2001cites this paper
• A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity

  2001cites this paper
• Lung cancer: therapeutic options for stage IV and recurrent NSCLC.

  2001cites this paper
• Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

  2000cites this paper
• Advanced Non-Small Cell Lung Carcinoma: The Emerging Role of Docetaxel

  2000cites this paper
• Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

  2000cites this paper
• Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.

  2000cites this paper
• Phase II Trial of Docetaxel in Asian Patients with Inoperable Stage III Non-Small Cell Lung Cancer

  2000cites this paper
• Risks and Benefits of Taxanes in Breast and Ovarian Cancer

  2000cites this paper
• Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine.

  2000cites this paper
• Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.

  2000cites this paper
• A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

  2000cites this paper
• Docetaxel: a review of its use in non-small cell lung cancer.

  2000cites this paper
• Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.

  1999cites this paper
• Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.

  1999cites this paper
• A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

  1999cites this paper
• Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

  1999cites this paper
• Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY

  1999cites this paper
• Clinical Pharmacokinetics of Docetaxel

  1999cites this paper
• New drug development: its role in reversing drug resistance.

  1999cites this paper
• Characteristics of Chemotherapy-induced Neuropathy: Clinical Studies on Cisplatin and Docetaxel

  1998cites this paper
• Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

  1998cites this paper
• In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.

  1998cites this paper
• Docetaxel: a taxoid for the treatment of metastatic breast cancer.

  1998cites this paper